GlassScriptPhysician profile
Steven A Occhiuti
NPI 1184723520
$2,165.63
in general payments reported to CMS, 2019-2025
25 companies · $581 in 2025
The $581 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $605 · 2022: $401 · 2023: $311 · 2024: $267 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $561.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.85 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $151.80 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $130.74 | 2021-2022 | |
| Novo Nordisk INC | $118.18 | 2021-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $95.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $72.89 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $61.29 | 2023-2024 | Seglentis, Zoryve |
| Sunovion Pharmaceuticals INC. | $54.97 | 2021 | |
| Optinose US, INC. | $54.73 | 2021-2023 | |
| Harmony Biosciences LLC | $50.03 | 2025 | |
| Phathom Pharmaceuticals, INC. | $36.74 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.33 | 2022 | |
| Endo Pharmaceuticals INC. | $21.49 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.77 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.59 | 2025 | Caplyta |
| Ani Pharmaceuticals, INC. | $16.82 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $16.68 | 2021 | |
| Hikma Pharmaceuticals USA | $15.23 | 2021 | |
| Glaxosmithkline, LLC. | $13.66 | 2021 | |
| Mylan Specialty L.P. | $11.70 | 2021 | |
| Sumitomo Pharma America, INC. | $10.50 | 2023 | Gemtesa |
| Genentech USA, INC. | $8.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Occhiuti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.